5 Stocks Pushing The Diversified Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 19 points (-0.1%) at 13,006 as of Monday, Dec. 3, 2012, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,239 issues advancing vs. 1,655 declining with 129 unchanged.

The Diversified Services industry currently is unchanged today versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Global Payments ( GPN), down 1.3%, Genpact ( G), down 1.5% and Tyco International ( TYC), down 1.2%. A company within the industry that increased today was Hertz Global Holdings ( HTZ), up 0.9%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Myriad Genetics ( MYGN) is one of the companies pushing the Diversified Services industry lower today. As of noon trading, Myriad Genetics is down $0.78 (-2.7%) to $27.94 on heavy volume Thus far, 1.4 million shares of Myriad Genetics exchanged hands as compared to its average daily volume of 670,100 shares. The stock has ranged in price between $26.87-$28.18 after having opened the day at $27.10 as compared to the previous trading day's close of $28.72.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. Myriad Genetics has a market cap of $2.4 billion and is part of the services sector. The company has a P/E ratio of 21.8, above the S&P 500 P/E ratio of 17.7. Shares are up 42.6% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Myriad Genetics a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Myriad Genetics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Myriad Genetics Ratings Report now.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

If you liked this article you might like

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma

Bullish and Bearish Reversals in the Market

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Gilead Sciences Leads Biotech Movers -- Plus Jim Cramer's Comments